NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased to announce that it will be presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, Florida.

NanoViricides announces herewith that the manufacture of the drug product for this clinical trial, "NV-387 Oral Gummies" is now complete, in anticipation of starting dosing in patients as soon as site readiness is established.

Anil R. Diwan, PhD, President and Executive Chairman of the Company will deliver a company presentation on Thursday, March 12th at 11:50 am ET, and will be available for one-on-one investor meetings throughout the event.

NV-387, NanoViricides' lead clinical stage drug, is an extremely broad-spectrum antiviral drug that is poised to revolutionize the treatment of respiratory antiviral infections just as antibiotics have revolutionized the treatment of bacterial infections. NV-387 has multiple indications in development, including, RSV, Influenza, Coronaviruses (including COVID), Monkeypox, Smallpox, Measles, as well as Viral Acute Respiratory Infections (V-ARI), and Severe ARIs (V-SARI).

NV-387, as an oral drug, has successfully completed a Phase I clinical trial and healthy human subjects with no dropouts and no reported adverse events, indicating excellent safety and tolerability.

NV-387 has been approved to enter a Phase II clinical trial for the treatment of Monkeypox (MPox) by the regulatory agency ACOREP of the Democratic Republic of Congo (DRC).

NanoViricides is developing first-in-class antiviral drugs that act by a novel mechanism of action, enabling unparalleled broad-spectrum antiviral activity as well as safety. The Nanoviricides technology defines a novel antiviral mode of action that we call "Re-Infection Inhibition". A "nanoviricide^™" is designed to look like a cell to the virus, presenting a high concentration of virus-binding ligands on its surface. Upon binding of the virus, the nanoviricide is further designed to change shape and engulf the virus particle, rendering it incapable of infecting cells.

Viruses are unlikely to escape the nanoviricide platform drugs, because the nanoviricide platform drugs mimic the essential feature on the hist cell that the viruses require, and continue to use, even as they go through a multitude of changes in their genomes and their protein makeup, via mutations, recombinations and in some cases, re-assortments.

About National Investment Banking Association (NIBA)

The National Investment Banking Association (NIBA) is a non-profit organization that has been serving the micro-cap and small-cap investment community for over 40 years. NIBA's 152nd Investment Conference website is available here:
https://nibas-152nd-investment-conference.events.accessnewswire.com/.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. NV-387 is a unique broad-spectrum antiviral that is also effective in animal models for Monkeypox (MPox), Smallpox, as well as Measles.

Our other advanced drug candidate is NV-HHV-1 for the treatment of all Herpesvirus infections including HSV-1 "cold sores", HSV-2 "genital ulcers, VZV Shingles and Chickenpox. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants.

NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

Forward-looking statements: This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Media Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

SOURCE: NanoViricides